Twenty-six patients presenting with 28 instances of mas• sive acute thrombotic obstruction of a prosthetic valve (16 mitral, 12 aortic) were treated with fibrinolytic agents. In 15 cases the patient presented with acute pulmonary edema and low cardiac output, in 10 with congestive heart failure and embolism and in 3 with peripheral embolism only. The diagnosis of thrombotic obstruction was made by echocardiography or cineradiography, in patients in whom the disc was immobile or barely mov• ing; cineangiography was necessary in only four pa• tients. The fibrinolytic agents administered were strep• tokinase, 2,000,000 U for 10 hours (14 cases), urokinase, 4,500 U/kg per h for 12 hours (7 cases), or the two agents successively (7 cases). Fibrinolysis was entirely successful in 19 patients: 18 are alive and well without surgical intervention after follow-up of 6 to 64 months and 1 patient had surgical revision after fibrinolysis. In two Despite improvements in the design of prosthetic cardiac valves, arterial thromboembolic complications after valve replacement remain a frequent cause of illness and mortality, often as a result of defects in anticoagulant therapy. An even more life-threatening event is massive thrombosis of the valve itself, which must be detected and treated promptly. Echocardiographic and cineradiographic studies of tilting disc valves are often helpful for early diagnosis. The re• ported incidence of thrombosis ranges from 0.5 to 5% (1) (2) (3) (4) , with a mortality rate of about 40% before or In spite of surgical treatment. Thrombectomy and debridement of the disc valve are the treatments usually favored in such cases, especially for aortic valves (5, 6) . However. many cata• strophically ill patients die suddenly before an operation can patients, fibrinolytic treatment was apparently success• ful but obstruction recurred 4 and 19 months later, re• spectively, and the patients were again treated by fibri• nolysis. In two patients complete failure of fibrinolytic treatment led to emergency surgery, and in three pa• tients improvement was incomplete and death occurred shortly after treatment.
No hemorrhagic complications were observed, but there were five cases of embolism during the fibrinolytic treatment. Fibrinolytic treatment would seem to be an attractive, nonsurgical alternative for the thrombosis of a valve prosthesis but, because of the risk of embolism with possible permanent damage, its use should be re• served for critically ill patients who are too sick to undergo immediate surgery.
(J Am Coil CardioI1986;7:743-51) be carried out. We tried fibrinolytic treatment in such pa• tients and, after its initial success, extended its use. This report describes our findings in 26 patients who presented with 28 instances of thrombotic obstruction of a tilting disc or bileaftet valve.
Methods
Patients in the study (Table 1) . Between June 1979 and June 1984 more than 1,000 prosthetic cardiac valves were implanted at our hospital. A great number of the pa• tients receiving these valves could not be retraced or died in unknown circumstances. In addition, three patients with prosthetic thrombosis, in whom fibrinolytic therapy was contraindicated, were treated surgically and are therefore not included in this report. During this period, we docu• mented 28 massive acute thromboses, which cannot be rep• resentative of all the complications that occurred. The 28 prosthetic valve obstructions occurred in 26 patients, 17 women and 9 men aged 17 to 81 years (mean 55.6), and involved 15 mitral prostheses (I with recurring thrombosis Clinical features. The main clinical signs at the time of acute thrombosis of the prosthesis are summarized in Table  1 . In 15 cases the patient had acute pulmonary edema. low cardiac output and hypotension; cardiac arrest occurred in 2 and ventricular fibrillation and tachycardia occurred in 2 others. In 10 cases the patient had subacute clinical dete• rioration, 5 presenting with congestive heart failure and peripheral or cerebral embolism and 3 presenting with sub• acute pulmonary edema and severe dyspnea. In the three remaining cases the symptoms were systemic embolic ep• isodes. The auscultatory findings were abnormal in all 28 cases: absent prosthetic clicks with loud systolic or diastolic murmurs in 19, muted or intermittent closing clicks with the appearance of unusually loud murmurs in 5 and only prominent systolic murmurs in 4. Chest roentgenograms showed evidence of pulmonary edema in 25 cases with enlargement of heart size in 16. (Table 2) confirmed the clinical indications of thrombosis of a prosthetic valve in all but the first two patients, who were in serious clinical condition. M-mode and two-di• mensional echocardiograms were obtained with a Varian 3000 or an RT 400 ultrasonoscope equipped with a 2.25 MHz transducer. The patients were examined in the supine position. The echocardiographic examination was per• formed in accordance with previously described standard techniques (7) (8) (9) . In each patient various transducer angu- 
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THROMBOSIS OF DISC V ALVES lations were attempted to obtain the maximal disc excursion. In 16 patients the tilting disc or the leaflets were radiopaque and allowed direct visualization of the disc motion by cineradiography. Following the technique described by Bjork et al. (10), the prosthesis was examined in two beam di• rections: a beam direction corresponding to the axis of mo• tion of the disc was found to calculate the maximal opening angle; a beam direction deviating 30 to 40° from the valve ring plane was used to study prosthetic valve closure. In four patients the diagnosis was not clearly confirmed by the preceding investigations and cardiac catheterization and an• giocardiography were performed.
Treatment. In all 28 cases of prosthetic thrombosis the patient was initially treated by fibrinolysis. The fibrinolytic agent was streptokinase (Streptase, Hoechst Laboratories, Germany) or urokinase (Urokinase, Choay Laboratories, France). In 14 cases streptokinase was infused in a periph• eral vein with an infusion pump for 10 hours and 20 minutes (loading dose of 500,000 U in 20 minutes followed by 1,500,000 U for 10 hours). In seven cases urokinase was infused under the same conditions for 12 hours at a constant dose (4,500 U/kg per h) without a loading dose. In seven cases, the first fibrinolytic agent used (streptokinase in five cases and urokinase in two) was insufficient and the other fibrinolytic agent was infused at the same dose 24 or 48 hours later. In all cases the choice of treatment was arbitrary. Urokinase and streptokinase were administered in the doses usually recommended in cases of pulmonary embolism (11) .
Heparin infusion was introduced after the fibrinolytic treatment, when the fibrinogen level was higher than 0.5 g/liter; this was usually 6 to 18 hours after the end of the fibrinolytic treatment. Heparin infusion to obtain a thrombin time at least twice the control value was continued for 7 to 10 days, then replaced by warfarin treatment adjusted to obtain optimal prothrombin times.
Blood coagulation tests were performed before fibrino• lytic treatment, at the end of treatment, 6 and 12 hours later and then daily. They included measurement of prothrombin time, cephalin-kaolin time, determination of fibrinogen by the chronomatic method of Van Clauss (2) , detection of fibrin/fibrinogen degradation products by means of latex particles coated with a new antibody (13) and determination of plasminogen level by chronometric method on chromo• genic substrate (14) .
Evaluation of the results of treatment was based on clin• ical and auscultatory findings and echocardiographic and cineradiographic studies. When necessary. right or left heart catheterization, or both, and cinecardiography were per• formed after treatment.
Results
Clinical results (Table 3 ). In 28 instances of acute thrombosis of a prosthetic heart valve in 26 patients, fi• brinolytic therapy was administered. The treatment was im- emergency operation was performed.
Echocardiographic results. An echocardiogram was performed in 15 patients with a mitral prosthetic valve. In 13, the patterns suggested thrombosis of the valve ( Fig. 1 ) with diminished amplitude of excursion, marked reduction of both the opening (24 to 184 mmls) and closing (90 to 380 mmls) rate of the disc and blunting of upstroke and downstroke. In two, the echocardiographic features were doubtful or did not suggest a thrombotic obstruction. After fibrinolytic treatment, all abnormal features disappeared in 11 of the 15 patients: opening rate increased from 144 ± 188 to 487 ± 175 mmls (p < 0.(01) and closing rate increased from 224 ± 105 to 753 ± 293 mrn/s (p < O.OOl) (Fig. 2) , disc excursion became normal and upstroke and downstroke were sharp. Eight thrombi around the prosthetic valve in the left atrium, evident on two-dimensional views, totally disappeared after treatment. In four patients abnormal valve features persisted with diminished opening and closing rates or intermittent reduction of disc excursion or blunt angles. One of these patients was operated on with success and the three others died a few days later without or despite surgery.
An echo cardiogram was performed in 10 patients with an aortic prosthetic valve. In only four patients was echo• cardiographic evidence of thrombosis obtained that included absence of disc motion, filling of the aortic root with dense, thick echoes and fluttering of the mitral valve (Fig. 3) . In four patients the echocardiographic pattern was doubtful and could not be used to determine the diagnosis even on two• dimensional views. Two echocardiograms allowed no di• agnosis of thrombosis (one St. Jude Medical valve seemed normal and there was one unsatisfactory recording). Fi• brinolytic treatment normalized the eight abnormal or doubt• ful echocardiographic patterns; after treatment, the record• ing showed a clearly moving disc in the aortic lumen and a normal mitral valve. Cineradiographic studies. In 16 patients the tilting disc or the leaflets were radiopaque. The diagnosis of thrombosis was simply and instantaneously confirmed in 11 patients in whom the disc was immobile, fixed in an intermediate po• sition (Fig. 4) or had an angle of motion less than 15°. In three patients the opening angle was 20 or 30°, in one patient the opening angle was 50° but closure was incomplete and in one patient the opening angle was 40°. After treatment the opening angle became normal (>45°) in 13 patients (Fig.  5) . In one patient the opening angle remained unchanged at 40° and death occurred 7 days later.
Angiocardiographic studies. Aortography was per• formed in two patients with a nonradiopaque St. Jude Med• ical valve in the aortic position. The cineangiograms showed severe aortic insufficiency and one leaflet remained fixed but these findings disappeared after fibrinolytic treatment. In two patients with a mitral Kaster-Omniscience nonradio• paque disc valve, cineangiograms revealed a marked delay of left atrial emptying, filling defects around the prosthesis and an immobile disc. Reexamination after treatment con• firmed normal disc motion and absence of thrombus in one of these patients. Fibrinolytic findings. In seven cases the patient re• ceived urokinase and streptokinase treatment successively. Therefore, 35 fibrinolytic treatments were administered (14 urokinase and 21 streptokinase). The fibrinogen levels de• creased with both streptokinase ( -78 ± 2%) and urokinase (-33 ± 18%) (p < 0.01). The plasminogen levels de• creased with streptokinase from 90.4 ± II to 8.8 ± 6%
and with urokinase from 88.8 ± 9 to 44.3 ± 21 % (p < 0.001). The mean level of fibrin/fibrinogen degradation products was 61.8 ± 26 jLg/ml after urokinase and 345.5 ± 410 jLg/ml after streptokinase (p < 0.05). How• ever, there was no correlation between the clinical course and the biologic results. In five cases of treatment failure or incomplete improvement, fibrinogen level decreased be• low 0.80 g/liter in three and was unchanged in two. On the other hand, among the 23 clinical successes, the fibrinogen and plasminogen levels remained unchanged, or fibrinogen was higher than 1.50 g/liter in 8 cases. Finally, we observed no difference between urokinase and streptokinase treat• ment: there were 14 urokinase treatments with 8 successes (64%) and 21 streptokinase treatments with 14 successes (66%). arterial thromboembolic complications appears to be the same with disc valve and ball valve prostheses (l). Only disc valves were involved in our study, which are the only type of valve inserted by our surgeons for hemodynamic reasons and because of their slight degree of hemolysis.
Predisposing factors. Many factors other than valve de• sign affect thromboemboiic complications. Long-term an• ticoagulant therapy is the most important (15-17). In our study 17 patients had no effective anticoagulant treatment. Anticoagulant therapy was not used in 4 of the 17 patients after St. Jude Medical valve insertion because of our initial policy, in 6 patients it was discontinued for medical reasons or by the patients themselves and in 7 patients receiving warfarin derivative treatment, control of prothrombin time was inefficient. Eleven patients had effective anticoagulant treatment at the time of thrombotic obstruction, but seven of them had had repeated normal or suboptimal prothrombin time at routine follow-up visits during tlie preceding months.
Atrial fibrillation (13 cases in our study) also increases the risk of thrombosis. Enlargement of the left atrium (two cases in but study) and previous valve infection (two cases) are additional risk factors.
Clinical features. The clinical characteristics of tlirom• bosis of prosthetic valves have been clearly defined by other investigators (3, 18, 19) . In most cases the clinical deterio• ration is acute and quickly becomes life-threatening. How• ever, in some patients signs of congestive heart failure and chest pain appear progressively a few weeks before the LEDAIN ET AL.
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THROMBOSIS OF DISC VALVES thrombotic dramatic accident. Five patients in our study had intermittent dyspnea or dizziness 2 months before hospital admission. Therefore, minimal symptoms in patients whose condition was good after valve replacement require careful investigation.
Diagnostic considerations. Echocardiographic study appears to be of considerable value in the diagnosis of tilting disc and leaflet valve thrombosis in the mitral position (9, 20) , where recording is not difficult and can be reproduced. In the case of massive thrombosis, the echocardiographic pat• tern is quite evident and diagnosis can be determined. With partial thrombosis, diagnosis is more difficult and compar• ison with a previous baseline echocardiogram is important. Time must be taken to identify intermittent reduction of disc motion or blunt angles and to evaluate reduction in opening and closing rates compared with rates in the postoperative baseline echocardiogram, Echocardiographic study of a prosthetic valve in the aortic position is more difficult and often unusable for diagnosis for technical reasons, despite use of the suprasternal and supraclavicular approach which may provide interesting information. With the St. Jude Med• ical valve in the aortic position, an echocardiogram may appear normal when only one mobile part of the valve is fixed. Thus, cardiac catheterization should be performed in patients in whom thrombosis is clinically suspected and a nondiagnostic echocardiogram should also be obtained (21) . Echocardiograms are also valuable in the assessment of the efficacy of fibrinolytic treatment. After treatment, the echo• cardiographic pattern of the prosthetic valve should become quite normal, similar to a postoperative one, with normal opening rate, closing rate and disc motion. All persisting ab• normal features must lead to angiographic study and surgery.
When the disc or the leaflets of the valve are radiopaque, cineradiography is the first examination to be used for di• agnosis. This method is simple and well tolerated by all patients, even when critically ill. The opening angles are not the same for different prosthetic valve types and depend on the trans valvular flow. Marked left ventricular failure may diminish the opening angle. Also, only a very reduced opening angle, far below that of the normal value (60° for Bjork-Shiley, 80° for Kaster-Omniscience and 90° for St. Jude Medical valves), associated or not with incomplete closure, confirms the diagnosis of thrombosis. The feature most often observed is a disc fixed in an intermediate po• sition or barely moving around this intermediate position.
In our experience, cineradiography affirmed the diagnosis in 15 of 16 examinations. When thrombosis of a prosthetic valve is clinically suspected, cineradiography should be the first examination because of the absence of risk and its rapidity and sensitivity. This study is also valuable in the assessment of fibrinolytic treatment; it can accurately eval• uate the extent to which the prosthesis has been cleared after treatment. Persistent reduction of an opening angle requires cardiac catheterization and surgery without delay.
Among patients in poor clinical condition with abnormal prosthetic sounds. the echocardiogram or cineradiogram, or both, always confirmed the diagnosis of thrombosis in our study. An angiographic examination was necessary in only four patients who were in relatively good condition with minimal symptoms but who were suspected of having pros• thetic thrombosis.
Therapeutic considerations. Massive thrombosis of a prosthetic cardiac valve is always a life-threatening event.
In three published studies (3, 5, 16) , the mortality rate was between 33 and 60.2% before or after reoperation. Simple thrombectomy on an aortic valve prosthesis seemed to give better results, with five successes in eight cases for Bjork and Henze (22) and seven consecutive successes for Ayuso et al. (5) . However, nonsurgical treatment is an attractive alternative, especially for very sick patients.
In the first patients to be treated with fibrinolysis for acute thrombotic obstruction of a prosthetic cardiac valve, reported in 1971 and 1977, the tricuspid valve was involved (23, 24) . In 1980, Witchitz et al. (25) reported on fibrinolytic treatment in 13 consecutive cases of thrombosis at mitral and aortic valves with a 70% success rate. Our study began in 1979 and includes 28 cases (26 patients). Fibrinolysis, without surgery, was entirely successful in 18 of these cases. The patients were followed up for 6 to 64 months without recurring thromboembolic accidents. These findings dem• onstrate that surgical intervention is not necessary after ef• fective thrombolytic treatment. All of these patients receive permanent adequate anticoagulant therapy. In two other pa• tients, all clinical and echocardiographic signs of valve dys• function disappeared with fibrinolysis, but thrombosis re• curred 4 and 19 months later, respectively, when anticoagulant therapy was ineffective. The recurrence probably repre• sented a new thrombotic obstruction rather than residual thrombus after the first treatment. In one patient, surgical revision after a second fibrinolytic treatment proved unnec• essary and the prosthetic valve was left in place. The final success rate was 21 (75%) of 28 cases.
In our study the fibrinolytic treatment took effect quickly (within 12 to 24 hours), with closing valve clicks reap• pearing suddenly. After that interval, absence of improve• ment or persistent signs of dysfunction require reoperation, which can be performed a few hours after fibrinolytic ac• tivity has been neutralized by protease inhibitors and fresh plasma. Two operations were performed in such circum• stances without hemorrhagic complications: one patient sur• vived and the other patient died of left ventricular failure on the third day after the operation.
The choice of either urokinase or streptokinase fibrino• lytic treatment was arbitrary and both agents were equally effective. In seven cases, the first treatment was only par• tially successful and persistent signs of dysfunction required a second treatment with the other drug 2 to 3 days later. It is possible that a longer initial period of treatment with the lACC Vol 7. No.4 Apnl 1986:743-51 first drug, over 24 or 36 hours, would give the same results.
In the other reported experiments, the dosage of drugs and times of infusion are variable and no conclusions can be reached. With our treatment, no hemorrhagic complications were observed and, in any event, these are not common. The major risk is embolism from thrombolysis of the valve thrombus. This complication is infrequent: 2 instances in the 13 patients of Witchitz et aI. (25) and 5 in 28 cases in our study. All the patients recovered with medication (fi• brinolysis) or surgical treatment (femoral embolism extrac• tion). Nevertheless, because small emboli could easily result in permanent brain damage such as hemiplegia we do not recommend the systematic use of fibrinolysis in all cases of thrombosis of prosthetic heart valves, but believe it should be reserved for critically ill patients who are too sick to undergo immediate surgery.
